Icares Medicus Inc (6612) - Total Liabilities
Based on the latest financial reports, Icares Medicus Inc (6612) has total liabilities worth NT$1.21 Billion TWD (≈ $38.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Icares Medicus Inc to track the company's year-over-year net asset growth rate.
Icares Medicus Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Icares Medicus Inc's total liabilities have evolved over time, based on quarterly financial data. See Icares Medicus Inc (6612) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Icares Medicus Inc Competitors by Total Liabilities
The table below lists competitors of Icares Medicus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aluko Co Ltd
KO:001780
|
Korea | ₩527.00 Billion |
|
Yen Sun Technology
TWO:6275
|
Taiwan | NT$2.23 Billion |
|
MegaStudy Co. Ltd
KQ:072870
|
Korea | ₩174.50 Billion |
|
Kamdhenu Limited
NSE:KAMDHENU
|
India | Rs531.83 Million |
|
Curo Holdings Co. Ltd
KQ:051780
|
Korea | ₩60.61 Billion |
|
WTK Holdings Bhd
KLSE:4243
|
Malaysia | RM673.11 Million |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
Turkey | TL1.41 Billion |
|
Maywood Acquisition Corp. 2 Class A Ordinary Share
NASDAQ:MYX
|
USA | $165.57K |
Liability Composition Analysis (2017–2025)
This chart breaks down Icares Medicus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Icares Medicus Inc (6612) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Icares Medicus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Icares Medicus Inc (2017–2025)
The table below shows the annual total liabilities of Icares Medicus Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.21 Billion ≈ $38.17 Million |
-2.71% |
| 2024-12-31 | NT$1.25 Billion ≈ $39.24 Million |
+419.36% |
| 2023-12-31 | NT$239.80 Million ≈ $7.55 Million |
+126.98% |
| 2022-12-31 | NT$105.65 Million ≈ $3.33 Million |
-27.12% |
| 2021-12-31 | NT$144.96 Million ≈ $4.57 Million |
-0.45% |
| 2020-12-31 | NT$145.62 Million ≈ $4.59 Million |
+4.75% |
| 2019-12-31 | NT$139.02 Million ≈ $4.38 Million |
+202.46% |
| 2018-12-31 | NT$45.96 Million ≈ $1.45 Million |
-29.19% |
| 2017-12-31 | NT$64.91 Million ≈ $2.04 Million |
-- |
About Icares Medicus Inc
ICARES Medicus, Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of ophthalmic medical devices in Taiwan, the United States, United Kingdom, Japan, Spain, China, Germany, and internationally. The company is also involved in the manufacturing, sales, and service of intraocular lenses (IOLs) and its implantation systems for use in treating cataract… Read more